A 3D QSAR analysis of in vitro binding affinity and selectivity of 3-isoxazolylsulfonylaminothiophenes as endothelin receptor antagonists

Quantitative Structure-Activity Relationships

Volumn 18, Issue 2, 1999, Pages 124-133

  Chen, Qi ^a   Wu, Chengde ^a   Maxwell, David ^a   Krudy, George A ^a   Dixon, Richard A F ^a   You, Tony J ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

3 Isoxazolylsulfonylaminothiophenes; Binding selectivity; Bioactive conformation; CoMFA; Endothelin antagonists

Indexed keywords

COMPUTATIONAL CHEMISTRY; HYDROGEN BONDS; MOLECULAR GRAPHICS; SULFUR COMPOUNDS;

3-ISOXAZOLYLSULFONYLAMINOTHIOPHENE; 3D-QSAR; BINDING AFFINITIES; BINDING SELECTIVITY; BIOACTIVE CONFORMATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; ENDOTHELIN; ENDOTHELIN ANTAGONIST; ENDOTHELIN RECEPTORS; PROPERTY;

BINDING ENERGY;

ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ISOXAZOLINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG CONFORMATION; HYDROGEN BOND; MOLECULAR INTERACTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0033019570     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-3838(199906)18:2<124::AID-QSAR124>3.0.CO;2-7     Document Type: Article

References (30)

1. Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. and Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 86, 2863-2867 (1989).
2. Haynes, W.G. and Webb, D.J. The endothelin family of peptides: Local hormones with diverse roles in health and disease? Clin. Sci. 84, 485-500 (1993).
3. Arai, H., Hori, T., Aramori, L., Ohkubo, H. and Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 348, 730-732 (1990).
4. Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. and Masaki, T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature (London) 348, 732-735 (1990).
5. Karne, S., Jayawlckreme, C.K. and Lerner, M.R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J. Biol. Chem. 268, 19126-19133 (1993).
6. A selectivity: Potency and solubility enhancing modification. J. Med. Chem. 35, 2139-2142 (1992).
7. A antagonist BMS-182874. J. Med. Chem. 37, 329-331 (1994).
8. A) receptor selective antagonists. J. Med. Chem. 38, 1259-1263 (1995).
9. A selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. 39, 1039-1048 (1996).
10. 2-aryl-3-(isoxazolysulfamonyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists. J. Med. Chem. 40, 1682-1689 (1997).
11. Wu, C., Chan, M.F., Stavros, F., Raju, B., Okun, I., Mong, S., Keller, K.M., Brock, T., Kogan, T.P. and Dixon, R.A. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonists. J. Med. Chem. 40, 1690-1697 (1997).
12. Clozel, M., Breu, V, Gray, G.A., Kalina, B., Loffler, B., Burri, K., Cassal, J., Hirth, G., Muller, M., Neidhart, W. and Ramuz, H. Pharmacological characterization of Bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270, 228-235 (1994).
13. Clozel, M., Breu, V., Burri, K., Cassal, J.-M., Fischli, W., Gray, G.A., Hirth, G., Loffler, B.-M., Muller, M., Neidart, W. and Ramuz, H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (London) 365, 759-761 (1993).
14. Elliott, J.D., Lago, M.A., Cousins, R.D., Gao, A., Leber, J.D., Erhard, K.F., Nambi, P., Elshourbagy, N.A., Kumar, C., Lee, J.A., Bean, J.W., DeBrosse, C.W., Eggleston, D.S., Brooks, D.P., Feuerstein, G., Ruffolo, R.R., Weinstock, J., Gleason, J.G., Peishoff, C.E. and Ohlstein, E.H. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J. Med. Chem. 37, 1553-1557 (1994).
15. Cody, W.L., He, J.X., DePue, P.L., Waite, L.A., Leonard, D.M., Sefler, A.M., Kaltenbronn, J.S., Haleen, S.J., Walker, D.M., Flynn, M.A., Welch, K.M., Reynolds, E.E. and Doherty, A.M. Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist AcDDip16-Leu-Asp-Ile-Ile-Trp21: Development of endothelin-B receptor selective antagonists. J. Med. Chem. 38, 2809-2819 (1995).
16. Ishikawa, K., Ihara, M., Noguchi, K., Mase, T., Mino, N., Saeki, T., Fukuroda, T., Fukami, T., Ozaki, S., Negase, T., Nishikibe, M. and Yano, M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. U.S.A. 91, 4892-4896 (1994).
17. Breu, V., Clozel, M., Burri, K., Hirth, G., Neidhart, W. and Ramuz, H. In vitro characterization of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ET-B receptor. FEBS Lett. 383, 37-41 (1996).
18. Saudek, V., Hoflack, J. and Pelton, J.T. Int. J. Peptide Protein Res. 37, 174-179 (1991).
19. Janes, R.W., Peapus, D.H. and Wallace, B.A. Nature, Struct. Biol. 1, 311-319 (1994).
20. Cowley, D.J. and Pelton, J.T. Solution conformational dynamics of the C-terminal residues in endothelin-1 and some analogues: A time-resolved fluorescence study. Int. J. Peptide Protein Res. 46, 56-64 (1995).
21. Cramer, R.D., III, Patterson, D.E. and Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967 (1988).
22. Krystek, S.R., Jr., Hunt, J.T., Stein, P.D. and Stouch, T.R. Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors. J. Med. Chem. 38, 659-668 (1995).
23. A-selective antagonists. J. Med. Chem. 38, 1344-1354 (1995).
24. Bell, P.H. and Roblin, R.O.J. Studies in chemotherapy. VII. A theory of the relation of structure to activity of sulfanilamide type compounds. J. Am. Chem. Soc. 64, 2905-2917 (1942).
25. Banner, D.W. and Hadvary, P. Crystallographic analysis at 3.0-Å resolution of the binding of human thrombin of four active site-directed inhibitors. J. Biol. Chem. 266, 20085-20093 (1991).
26. Saunders, M., Houk, K.N., Wu, Y.-D., Still, W.C., Lipton, M., Chang, G. and Guida, W.C. Conformations of cycloheptadecane - a comparison of methods for conformational searching. J. Am. Chem. Soc. 112, 1419-1427 (1990).
27. SYBYL Molecular Modeling System (V6.4), TRIPOS Associates, St. Louis, MO.
28. Greco, G., Novellino, E., Silipo, C. and Vittoria, A. Comparative molecular field analysis on a set of muscarinic agonists. Quant. Struct.-Act. Relat. 10, 289-299 (1991).
29. van de Waterbeemd, H. The history of drug research: from Hansch to the present. Quant. Struct. Act. Relat. 11, 200 (1992).
30. Zhu, Q., Guo, Z., Huang, N., Wang, M. and Chu, F. Comparative molecular field analysis of a series of paclitaxel analogues. J. Med. Chem. 40, 4319-4328 (1997).